CANBRIDGE PHARM.DL-00001
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatme… Read more
CANBRIDGE PHARM.DL-00001 (MF1) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CANBRIDGE PHARM.DL-00001 (MF1) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CANBRIDGE PHARM.DL-00001 - Net Assets Trend (None–None)
This chart illustrates how CANBRIDGE PHARM.DL-00001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CANBRIDGE PHARM.DL-00001 (None–None)
The table below shows the annual net assets of CANBRIDGE PHARM.DL-00001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CANBRIDGE PHARM.DL-00001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CANBRIDGE PHARM.DL-00001 Competitors by Market Cap
The table below lists competitors of CANBRIDGE PHARM.DL-00001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
North Media A/S
CO:NORTHM
|
$61.07 Million |
|
AROBS TRANSILVANIA SOFTWARE SA
RO:AROBS
|
$61.08 Million |
|
Insas Bhd
KLSE:3379
|
$61.08 Million |
|
GENASYS INC. DL-00001
F:G66
|
$61.08 Million |
|
KNH Enterprise Co Ltd
TW:9919
|
$61.01 Million |
|
Esprit Holdings Limited
PINK:ESHDF
|
$60.99 Million |
|
GNA Axles Limited
NSE:GNA
|
$60.95 Million |
|
Racing Force S.p.A.
PA:ALRFG
|
$60.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CANBRIDGE PHARM.DL-00001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CANBRIDGE PHARM.DL-00001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CANBRIDGE PHARM.DL-00001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CANBRIDGE PHARM.DL-00001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CANBRIDGE PHARM.DL-00001 (MF1) | €- | N/A | N/A | $61.07 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |